Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Galaxia SM Inc
KRX:011420
|
KR |
|
Novogene Co Ltd
SSE:688315
|
CN |
|
British American Tobacco PLC
LSE:BATS
|
UK |
|
S
|
Singapore Technologies Engineering Ltd
OTC:SGGKF
|
SG |
|
S
|
Song Da No 11 JSC
VN:SJE
|
VN |
|
Elkem ASA
OSE:ELK
|
NO |
|
A
|
Al-Salam Real Estate Investment Trust
KLSE:ALSREIT
|
MY |
|
Pentamaster International Ltd
HKEX:1665
|
MY |
|
Wonderfi Technologies Inc
TSX:WNDR
|
CA |
|
Luks Kadife Ticaret ve Sanayi AS
IST:LUKSK.E
|
TR |
|
Greatwalle Inc
HKEX:8315
|
HK |
Novan Inc
Total Current Liabilities
Novan Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Total Current Liabilities
$46.4m
|
CAGR 3-Years
53%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$37B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$35.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Total Current Liabilities?
Total Current Liabilities
46.4m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Total Current Liabilities amounts to 46.4m USD.
What is Novan Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
39%
Over the last year, the Total Current Liabilities growth was 316%. The average annual Total Current Liabilities growth rates for Novan Inc have been 53% over the past three years , 39% over the past five years .
